Program
RB-ADSC
Its studies are mostly in Alzheimer Disease, led by Regeneration Biomedical.
Furthest: phase 2, since Sep 17, 20253 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneration Biomedical | 32 open or running | phase 2since Sep 17, 2025 | Dec 1, 2022 | Sep 2028phase 1 · NCT07373067 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2022First study: phase 1 study in Alzheimer DiseaseFirst studyNCT05667649 · 7 enrolled · United States
- Sep 17, 2025Phase 2 study in Alzheimer DiseaseNCT07205601 · 115 planned
- Jan 15, 2026Phase 1 study in Alzheimer DiseaseNCT07373067 · 9 planned
Ahead
- Sep 2028Primary completion: phase 1 study in Alzheimer DiseaseNCT07373067
- Feb 2029Primary completion: phase 2 study in Alzheimer DiseaseNCT07205601
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07373067Alzheimer Disease | 1 | Not yet recruiting | Sep 2028 | 9 |
| NCT07205601Alzheimer Disease | 2 | Not yet recruiting | Feb 2029 | 115 |
| NCT05667649Alzheimer Disease · United States | 1 | Completed | Jun 25, 2026 | 7 |
How it is read
Names in the registry
- “RB-ADSC”, 3 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.